REPLIGEN CORP Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
REPLIGEN CORP (RGEN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.93 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-17.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2022-02-17
- REPLIGEN CORP effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2021 was $1.93M, a 115.40% increase from fiscal 2020.
- REPLIGEN CORP effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2020 was $896.00K, a 873.91% increase from fiscal 2019.
- REPLIGEN CORP effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2019 was $92.00K, a 5.15% decline from fiscal 2018.
- REPLIGEN CORP effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2018 was $97.00K, a 52.68% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month as first filed |
|---|---|---|
| 2021-12-31 | $1.93M 10-K · filed 2022-02-17 | |
| 2020-12-31 | $896.00K 10-K · filed 2022-02-17 | |
| 2019-12-31 | $92.00K 10-K · filed 2022-02-17 | |
| 2018-12-31 | $97.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $205.00K 10-K · filed 2020-02-26 | $470.00K 10-K · filed 2018-02-22 |
| 2016-12-31 | $380.00K 10-K · filed 2019-03-01 | |
| 2015-12-31 | -$230.00K 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |